请使用支持JavaScript的浏览器! LC Labs/N-9077 Nintedanib, Free Base, >99%/N-9077/2 g-蚂蚁淘商城
新闻动态

LC Labs/N-9077 Nintedanib, Free Base, >99%/N-9077/2 g

  
  2025-07-05
  
  • This product was previously Cat. No. I-9077, Intedanib, and Cat. No. V-9077, Vargatef.
  • This research compound is the free base form of nintedanib. We also offer the ethanesulfonate salt form; please see Nintedanib, Ethanesulfonate Salt, Cat. No. N-9055.
  • Nintedanib is an indolinone derivative that potently inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) kinase activity in enzymatic assays (table 1). It blocks mitogen-activated protein kinase and Akt signaling pathways in three cell types contributing to angiogenesis, namely endothelial cells, pericytes, and smooth muscle cells, and it inhibits cell proliferation with an EC50 of 10-80 nM. Hilberg, F., et al. \"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.\" Cancer Res. 68: 4774-4782 (2008).
  • Table 1. In vitro kinase inhibition profile of Nintedanib(adapted from Hilberg, F., et al. 2008).KinaseIC50 (nM)*VEGFR-2 (mouse)13 ± 4VEGFR-313 ± 10Lck16 ± 16VEGFR-221 ± 13Flt-326VEGFR-134 ± 15FGFR-237 ± 2PDGFRα59 ± 71PDGFRβ65 ± 7FGFR-169 ± 70FGFR-3108 ± 41Src156 ± 40Lyn195 ± 12FGFR-4610 ± 117IGF1R>1,000InsR>4,000CDK1>10,000CDK2>10,000CDK4>10,000Other kinases (n = 26)>10,000EGFR>50,000HER2>50,000* Assays performed with ATP concentrations at the respective Ki. Human kinases were tested except when stated otherwise. Phosphatase PP2A and another 25 kinases were analyzed at 10 µM with 100 µM ATP: GSK3B, ROCKII, DYRK1A, PKCα, MAPK2ERK2, HGFR, MSK1, PDK1, CHK1, MAPKAPK2, SAPK2AP38, S6K1, SGK, CK1, CK2, PKA, SAPK2BP38B2, SAPK3P38G, JNK1A1, SAPK4P38D, PHK, PKBA, CSK, CDK2/CYCLINA, PRAK (data not shown).
  • Nintedanib significantly decreased blood vessel area and inhibited tumour growth. Zips, D., et al. \"Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.\" Radiother. Oncol. 92: 405-410 (2009).
  • A reproducible hepatic perfusion index (HPI) was determined by using quantified gadopentetate dimeglumine (Gd-DTPA) concentration. The HPI decreased significantly at 28 days after treatment with nintedanib. HPI may be useful for monitoring antiangiogenic treatment response of hepatic metastases. Miyazaki, K., et al. \"Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor.\" Eur. Radiol. 18: 1414-1421 (2008).
  • Nintedanib is the active ingredient in the drug formulation designated by the trade name Vargatef®. This drug has been used in human clinical trials for patients with non-small cell lung, colorectal, uterine, endometrial, ovarian, and cervical cancer and multiple myeloma. NOTE: THE NINTEDANIB, ETHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT VARGATEF®, AND IS NOT FOR HUMAN USE.
  • This nintedanib product is the free base form, whose CAS number is given above. The CAS number of the Nintedanib, Ethanesulfonate Salt form is 656247-18-6.
  • Another CAS number previously assigned to Nintedanib, Free Base, namely 928326-83-4 has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.

Related Terms:

[BIBF1120] [Intedanib] [Vargatef]M.W. 539.62C31H33N5O4[656247-17-5]M.I. 15: 5031

Storage

Store at or below -20 ºC

Solubility

Soluble in DMSO at 25 mg/mL with warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility

Disposal

A

本文链接: https://www.ebiomall.cn/b472-vlabs/info-1567351192.html

免责声明 本文仅代表作者个人观点,与本网无关。其创作性以及文中陈述文字和内容未经本站证实,对本文以及其中全部或者部分内容、文字的真实性、完整性、及时性本站不做任何保证或承诺,请读者仅作参考,并请自行核实相关内容。
版权声明 未经蚂蚁淘授权不得转载、摘编或利用其他方式使用上述作品。已经经本网授权使用作品的,应该授权范围内使用,并注明“来源:蚂蚁淘”。违反上述声明者,本网将追究其相关法律责任。
没有了